Document is current
Any future updates will be listed below
-
Authors
Volkmann, Elizabeth R.
Wilhalme, Holly
Good, Sam
Kim, Grace Hyun J.
Goldin, Jonathan
Roth, Michael D.
Tashkin, Donald P.
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K23 HL150237)
- License Information
-
More Information
Article History
Received: 21 August 2025
Accepted: 19 October 2025
First Online: 28 November 2025
Declarations
:
: The Institutional Review Board of each of the SLS I and II study sites approved this study, and informed consent was obtained by all participants.
: Not applicable.
: Elizabeth R. Volkmann reports the following financial relationships outside of the submitted work on SLSI and II outcomes: Consulting fees from Boehringer Ingelheim, BMS, GSK; Speaking fees (unbranded disease state lectures) from Boehringer Ingelheim; Grant support from Kadmon, Horizon Therapeutics, Prometheus, Boehringer Ingelheim, GSK, AstraZeneca. Holly Wilhalme reports no competing interests. Sam Good reports no competing interests. Grace Hyun J. Kim reports being a research consultant for MedQIA and has an issue patent UC-2015-0324982-A1. Jonathan Goldin reports no relevant financial disclosures. He reports being the founder of MedQIA and has an issue patent UC-2015-0324982-A1. Donald P. Tashkin reports receiving modest financial support from Genentech for participation in an investigator-initiated trial outside of the submitted work. Michael D. Roth reports receiving institution support from Genentech for leading an investigator-initiated clinical trial in SSc-ILD outside of the SLS I and II study reported here.
